BBIO - BridgeBio Pharma - Stock Price & Dividends

BridgeBio Pharma Inc. is a pioneering biopharmaceutical company that focuses on developing innovative medicines to transform the lives of patients suffering from genetic diseases and cancers. By leveraging cutting-edge science and technology, the company discovers, creates, tests, and delivers groundbreaking treatments that address significant unmet medical needs.

The company's robust pipeline includes several promising product candidates in various stages of development. For instance, AG10, a next-generation oral small molecule, is currently in Phase 3 clinical trials for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), a debilitating condition that affects the heart. Additionally, low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, is being evaluated in a Phase 3 study as a potential treatment option for children with achondroplasia, a genetic disorder that affects bone growth.

BridgeBio Pharma is also advancing BBP-631, an AAV5 gene transfer product candidate, in a Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia (CAH), a rare genetic disorder that affects the adrenal glands. Furthermore, the company is developing Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR), in a Phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic disorder that affects calcium levels in the blood.

In addition to these programs, the company is exploring BBP-418, a glycosylation substrate pro-drug, in a Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), a rare genetic disorder that affects muscle function. BridgeBio Pharma's diverse pipeline also includes products in development for mendelian, oncology, and gene therapy diseases, underscoring the company's commitment to addressing a broad range of unmet medical needs.

Through strategic collaborations and license agreements with esteemed institutions such as the Leland Stanford Junior University and Leidos Biomedical Research, Inc., BridgeBio Pharma is well-positioned to accelerate the development of its innovative therapies. Founded in 2015 and headquartered in Palo Alto, California, the company is driven by a passion to improve human health and quality of life.